Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838287 · ClinicalTrials.gov registry record · Phase 4
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
A Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT05838287: Recruiting Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese, sponsored by The University of Texas Health Science Center at San Antonio.
NCT05838287 is a Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 78 participants, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05838287, a Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Primary Outcome
Measurement of change in systolic function of the heart using cardiac MRI
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
Study Locations (1)
Texas
- Texas Diabetes Institute/UH - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2030-01 |
| Phase | Phase 4 |
What NCT05838287 shows while recruiting
NCT05838287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05838287 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05838287 about?
NCT05838287 is a clinical study titled "Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants". Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathop...
What is the current status of trial NCT05838287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2023-07-10. Estimated completion is 2030-01.
What conditions does trial NCT05838287 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes Mellitus in Obese.
What interventions are being tested in trial NCT05838287?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT05838287?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838287 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05838287's enrollment target sits among peer trials
78 21st of 42 higher than 21 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
RECRUITING · Phase 4
-
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
COMPLETED · Phase 4
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI